

EURECA-m & CKD-MBD CME Meeting

September 13-15, 2018

Macedonia Palace Hotel

Thessaloniki, Greece

Thursday, September 13

16:30 Registrations

17:00-17:15 Welcome and Introduction

P. Sarafidis, A. Papagianni

17:15-18:00 *Session 1*

Introductory Lecture on History of Nephrology topic

18:00-20:00 *Session 2*

- Raymond Vanholder
- Jolanta Malyszko

Metabolomics approach to cardiovascular risk in CKD
Atrial Fibrillation in CKD: an unduring, scarcely focused problem

- Aikaterini Papagianni

An update on the role of FGF-23 and Klotho axis in cardiovascular disease

- Francesca Mallamaci

Sleeping disordered breathing in CKD: relevance for cardiovascular and renal outcomes

Friday, September 14

09:00-11:00 *Session 3*

- Mario Cozzolino
- Etienne Cavalier
- Peter Stenvinkel

Vitamin D rehabilitated for vascular health

Biomarkers from bone.....and beyond!

Inflammation at the crossroad of MBD and cardiovascular disease

- Ziad A. Massy

Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney Disease

11:00-11:30 Coffee-Break

11:30-13:30 *Session 4*

- Patrick Rossignol

Resistant hypertension in CKD: epidemiology and pathophysiology

- Costas Tsioufis

Update on pharmaceutical and interventional treatment of resistant hypertension

- Andrzej Więcek

Renal denervation – a chance to slow the CKD progression?

- Pantelis Sarafidis

Ambulatory BP, pulse wave analysis and BP variability: potential value in dialysis

13:30-15:00 Lunch Break

15:00-17:00 Session 5

- Charles Ferro

Myocardial fibrosis in CKD - from clinic to laboratory and back to the clinic

- Gunnar Heine

Treatment of HF with reduced ejection fraction in CKD patients

- Patrick Mark

Stroke and vascular cognitive decline in CKD- what are the targets for intervention?

- Apostolos Tsapas

Cardiovascular and renal effects of SGLT-2: a unique opportunity for diabetic patients with CKD?

17:00-17:15 Coffee-Break

17:15-19:00 Session 6

- Jose Valdivielso

Atherosclerosis in CKD: is it really different from the general population?

- Robert Ekart

Obesity in patients with CKD: an unappreciated epidemic?

- Mehmet Kanbay

An update about uric acid in CKD: What should we know and do?

- Michael Dumas

Sexual dysfunction in CKD: a circulatory defect or more?

Saturday, September 15

09:00-11:00 Session 7

- Joao Frazão

The Bone-Vessel axis

- Marc Vervloet

Vascular phosphate toxicity revisited

- Mariano Rodriguez

The role of dietary fat in vascular calcification

- Gerard London

Parathyroid Hormone as a cardiovascular risk factor in CKD: a reassessment in 2018

11:00-11:15 Coffee-Break

11:15-13:15 Session 8

- Pablo Ureña-Torres

Effects of antihypertensive treatment on the skeleton")?

- Alberto Ortiz

Sex differences in CKD incidence and outcomes: beyond sex hormones?

- Marianne Verhaar

Regenerative nephrology: a 2018 update

- Danilo Fliser

RAAS blockade and hyperkalemia - a cause of concern or not?

13:15-13:30 Conclusions

P. Sarafidis, D. Goumenos